SCHEMBL30159127

SCHEMBL30159127

CC[C@H](C)[C@H](NC(=O)[C@H](CCSC)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)O

nearest known ligand 0.58

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ RXFP1 Q9HBX9 8/20 0.54
▸ PTH1R Q03431 6/20 0.53
▸ BACE1 P56817 1/20 0.52
▸ VIPR1 P32241 1/20 0.49
▸ CCKBR P32239 1/20 0.49
▸ GLP1R P43220 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30159324 0.95 BACE1 (0.56) RXFP1PTH1RBACE1VIPR1GLP1R
SCHEMBL30159280 0.94 BACE1 (0.54) RXFP1PTH1RBACE1VIPR1GLP1R
SCHEMBL30159188 0.93 PTH1R (0.57) RXFP1PTH1RBACE1VIPR1CCKBR
SCHEMBL30159395 0.91 BACE1 (0.51) RXFP1PTH1RBACE1VIPR1GLP1R
SCHEMBL30906349 0.90 RXFP1 (0.57) RXFP1PTH1RCCKBRGLP1R
SCHEMBL30437160 0.90 BACE1 (0.56) RXFP1PTH1RBACE1VIPR1CCKBR
SCHEMBL30495796 0.87 RXFP1 (0.59) RXFP1PTH1RVIPR1CCKBRGLP1R
SCHEMBL30433492 0.87 PTH1R (0.57) RXFP1PTH1RVIPR1CCKBRGLP1R
SCHEMBL30599009 0.87 PTH1R (0.55) RXFP1PTH1RBACE1VIPR1GLP1R
SCHEMBL31465333 0.86 VIPR1 (0.52) RXFP1PTH1RVIPR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260071353-A1 SUBSTRATES, PEPTIDE ARRAYS, AND METHODS VIBRANT HOLDINGS LLC (US) 2026-03-12 — — US disclosed
US-12454771-B2 Substrates, peptide arrays, and methods VIBRANT HOLDINGS LLC (US) 2025-10-28 — — US disclosed
EP-4556467-A2 METHODS FOR ARRAY SYNTHESIS Vibrant Holdings, LLC (US) 2025-05-21 — — EP disclosed
US-12251674-B2 Substrates, systems, and methods for array synthesis and biomolecular analysis VIBRANT HOLDINGS, LLC (US) 2025-03-18 — — US disclosed
EP-3617219-B1 METHODS FOR ARRAY SYNTHESIS VIBRANT HOLDINGS LLC (US) 2025-02-26 — — EP disclosed
US-20230294063-A1 SUBSTRATES, PEPTIDE ARRAYS, AND METHODS VIBRANT HOLDINGS, LLC 2023-09-21 — — US disclosed
US-11565231-B2 Substrates, peptide arrays, and methods VIBRANT HOLDINGS, LLC (US) 2023-01-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230294063-A1 SUBSTRATES, PEPTIDE ARRAYS, AND METHODS VIP, IAPP, GIPR RXFP1 777/4885PTH1R 549/4885BACE1 791/4885
US-20260071353-A1 SUBSTRATES, PEPTIDE ARRAYS, AND METHODS VIP, CALCB, SPPL2B RXFP1 1521/4885PTH1R 208/4885BACE1 401/4885
US-11565231-B2 Substrates, peptide arrays, and methods VIP, IAPP, GIPR RXFP1 777/4885PTH1R 549/4885BACE1 791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback